ZETOMIPZOMIB (KZR-616) clinical trials

A Phase 2b, Randomized, Controlled Double-blind, Multicenter Study Comparing the Efficacy and Safety of Zetomipzomib (KZR-616) 30 mg or 60 mg with Placebo in Patients with Active Lupus Nephritis

This study is looking at a new medicine called Zetomipzomib (KZR-616) for people with lupus affecting their kidneys. Researchers want to see if it's safe and helps improve kidney function compared to existing treatments, using different dose levels.